Benyahia, Z.; Blackman, M.C.N.M.; Hamelin, L.; Zampieri, L.X.; Capeloa, T.; Bedin, M.L.; Vazeille, T.; Schakman, O.; Sonveaux, P.
In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers 2021, 13, 569.
https://doi.org/10.3390/cancers13030569
AMA Style
Benyahia Z, Blackman MCNM, Hamelin L, Zampieri LX, Capeloa T, Bedin ML, Vazeille T, Schakman O, Sonveaux P.
In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers. 2021; 13(3):569.
https://doi.org/10.3390/cancers13030569
Chicago/Turabian Style
Benyahia, Zohra, Marine C. N. M. Blackman, Loïc Hamelin, Luca X. Zampieri, Tania Capeloa, Marie L. Bedin, Thibaut Vazeille, Olivier Schakman, and Pierre Sonveaux.
2021. "In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment" Cancers 13, no. 3: 569.
https://doi.org/10.3390/cancers13030569
APA Style
Benyahia, Z., Blackman, M. C. N. M., Hamelin, L., Zampieri, L. X., Capeloa, T., Bedin, M. L., Vazeille, T., Schakman, O., & Sonveaux, P.
(2021). In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers, 13(3), 569.
https://doi.org/10.3390/cancers13030569